127 related articles for article (PubMed ID: 2965409)
1. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis.
Petersson F; Hammar M; Mathson K; Hjertberg H; Varenhorst E
Scand J Urol Nephrol; 1987; 21(4):267-71. PubMed ID: 2965409
[TBL] [Abstract][Full Text] [Related]
2. Effects of the gonadotrophin-releasing hormone agonist 'Zoladex' upon pituitary and gonadal function in hypogonadal (hpg) male mice: a comparison with normal male and testicular feminized (tfm) mice.
Scott IS; Bennett MK; Porter-Goff AE; Harrison CJ; Cox BS; Grocock CA; O'Shaughnessy PJ; Clayton RN; Craven R; Furr BJ
J Mol Endocrinol; 1992 Jun; 8(3):249-58. PubMed ID: 1385960
[TBL] [Abstract][Full Text] [Related]
3. Testosterone and gonadotrophin profiles in patients on daily or monthly LHRH analogue ICI 118630 (Zoladex) compared with orchiectomy.
Grant JB; Ahmed SR; Shalet SM; Costello CB; Howell A; Blacklock NJ
Br J Urol; 1986 Oct; 58(5):539-44. PubMed ID: 2946356
[TBL] [Abstract][Full Text] [Related]
4. Effects of a gonadotropin-releasing hormone agonist analog (ICI 118630) on endocrine functions of human testis in vivo and in vitro.
Namiki M; Nonomura N; Nakamura M; Okuyama A; Sonoda T; Nishimune Y; Matsumoto K
Fertil Steril; 1987 Dec; 48(6):1012-7. PubMed ID: 2960563
[TBL] [Abstract][Full Text] [Related]
5. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
Mahler C; Verhelst J; Chaban M; Denis L
Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
[TBL] [Abstract][Full Text] [Related]
6. Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
Murphy GP; Greco J; Huben R
Urology; 1987 Nov; 30(5):482-3. PubMed ID: 2960064
[TBL] [Abstract][Full Text] [Related]
7. Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118-630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer.
Kuber W; Viehberger G; Zeillinger R; Spona J
Urol Res; 1991; 19(1):19-24. PubMed ID: 1827557
[TBL] [Abstract][Full Text] [Related]
8. Zoladex: a sustained-release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer.
Ahmann FR; Citrin DL; deHaan HA; Guinan P; Jordan VC; Kreis W; Scott M; Trump DL
J Clin Oncol; 1987 Jun; 5(6):912-7. PubMed ID: 2953870
[TBL] [Abstract][Full Text] [Related]
9. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
Huhtaniemi I; Nikula H; Rannikko S
J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
[TBL] [Abstract][Full Text] [Related]
10. Pituitary hyperplasia after goserelin (LHRH-analogue) therapy.
Radner H; Pummer K; Lax S; Wandschneider G; Höfler H
Neuropathol Appl Neurobiol; 1991 Feb; 17(1):75-81. PubMed ID: 1647501
[TBL] [Abstract][Full Text] [Related]
11. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
[TBL] [Abstract][Full Text] [Related]
12. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
13. [Change of serum adrenal androgens in prostatic cancer patients after bilateral orchidectomy or LHRH agonist treatment].
Oka H; Negoro H; Sugino Y; Iwamura H; Moroi S; Kawakita M
Hinyokika Kiyo; 2003 Sep; 49(9):521-5. PubMed ID: 14598689
[TBL] [Abstract][Full Text] [Related]
14. Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
Huhtaniemi I; Nikula H; Rannikko S
J Clin Endocrinol Metab; 1985 Oct; 61(4):698-704. PubMed ID: 2993345
[TBL] [Abstract][Full Text] [Related]
15. [Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].
Usami M; Kotake T; Matsuda M; Okajima E; Osafune M; Sonoda T
Hinyokika Kiyo; 1987 Jan; 33(1):141-50. PubMed ID: 2953179
[TBL] [Abstract][Full Text] [Related]
16. Renewal timing of long-acting depot luteinizing hormone-releasing hormone agonist (Zoladex) is critical in the treatment of hormone-dependent rat prostatic carcinoma (R3327-H).
Geldof AA; de Voogt HJ; Rao BR
Prostate; 1987; 11(3):281-90. PubMed ID: 2960958
[TBL] [Abstract][Full Text] [Related]
17. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
[TBL] [Abstract][Full Text] [Related]
19. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
[TBL] [Abstract][Full Text] [Related]
20. Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists.
Huhtaniemi I; Nikula H; Rannikko S; Clayton R
J Steroid Biochem; 1986 Jan; 24(1):169-76. PubMed ID: 3009972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
